Leerink Partnrs Forecasts Increased Earnings for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at Leerink Partnrs increased their FY2027 earnings estimates for shares of REGENXBIO in a note issued to investors on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($1.25) per share for the year, up from their previous forecast of ($1.87). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2028 earnings at $1.10 EPS.

Several other research firms have also recently issued reports on RGNX. Barclays decreased their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Raymond James reaffirmed an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. HC Wainwright increased their price objective on shares of REGENXBIO from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, REGENXBIO presently has an average rating of “Moderate Buy” and a consensus price target of $35.64.

REGENXBIO Stock Performance

Shares of RGNX opened at $9.63 on Thursday. The firm has a market capitalization of $477.07 million, a price-to-earnings ratio of -1.91 and a beta of 1.23. REGENXBIO has a 52 week low of $8.53 and a 52 week high of $28.80. The business’s fifty day moving average price is $10.37 and its two-hundred day moving average price is $12.14.

Hedge Funds Weigh In On REGENXBIO

Large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC boosted its position in REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 3,720 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of REGENXBIO in the second quarter valued at approximately $121,000. Finally, Arizona State Retirement System raised its holdings in shares of REGENXBIO by 20.6% in the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,997 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.13% of the stock is currently owned by insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.